Last reviewed · How we verify
Thiazide Treatment Group
Thiazide diuretics reduce blood pressure by decreasing sodium reabsorption in the distal convoluted tubule of the kidney, leading to increased sodium and water excretion and reduced blood volume.
Thiazide diuretics reduce blood pressure by decreasing sodium reabsorption in the distal convoluted tubule of the kidney, leading to increased sodium and water excretion and reduced blood volume. Used for Hypertension, Edema associated with congestive heart failure, hepatic cirrhosis, or renal disease.
At a glance
| Generic name | Thiazide Treatment Group |
|---|---|
| Sponsor | Cedars-Sinai Medical Center |
| Drug class | Thiazide diuretic |
| Target | Sodium-chloride cotransporter (NCC) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Thiazides inhibit the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, preventing sodium reabsorption and promoting urinary sodium and water loss. This reduces intravascular volume and peripheral vascular resistance, resulting in lower blood pressure. They also have a direct vasodilatory effect on arterioles that contributes to their antihypertensive action.
Approved indications
- Hypertension
- Edema associated with congestive heart failure, hepatic cirrhosis, or renal disease
Common side effects
- Hypokalemia
- Hyperglycemia
- Hyperuricemia
- Hyponatremia
- Ototoxicity (high doses)
- Photosensitivity
Key clinical trials
- POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure (PHASE2, PHASE3)
- Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control (NA)
- Validation of New Diagnostic Indices to Simplify Hyponatremia Therapy Assessment in Patients on Thiazide Diuretics (NA)
- A Study of Blood Pressure Control During Cancer Treatment (PHASE2)
- Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Acute Decompensated Heart Failure (NA)
- Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction (EARLY_PHASE1)
- Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO) (NA)
- Mitigating the Pro-inflammatory Phenotype of Obesity (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thiazide Treatment Group CI brief — competitive landscape report
- Thiazide Treatment Group updates RSS · CI watch RSS
- Cedars-Sinai Medical Center portfolio CI